ライフサイエンスコーパス: cardiogenic shock

1 onprocedural outcomes (eg, stroke, bleeding, cardiogenic shock).

2 tion (VA-ECMO) is increasingly used to treat cardiogenic shock.

3 tegies during VA-ECMO in adult patients with cardiogenic shock.

4 inical parameters for risk stratification in cardiogenic shock.

5 rcutaneous mechanical circulatory support in cardiogenic shock.

6 trength of association with and relevance to cardiogenic shock.

7 prospective European multinational study of cardiogenic shock.

8 al variables have been used to judge risk in cardiogenic shock.

9 osis is similar in patients with and without cardiogenic shock.

10 ggressive management of patients who develop cardiogenic shock.

11 ic bradycardia, symptomatic hypotension, and cardiogenic shock.

12 rogressive muscle weakness was admitted with cardiogenic shock.

13 ne oxygenation for refractory postcardiotomy cardiogenic shock.

14 responsive and was found to be in a state of cardiogenic shock.

15 1 patients, 49 with septic shock and 22 with cardiogenic shock.

16 oronary intervention (PCI) in the setting of cardiogenic shock.

17 ematoma or hemorrhage, blood transfusion, or cardiogenic shock.

18 rrent pharmacological agents utilized during cardiogenic shock.

19 ical efficacy of these devices in refractory cardiogenic shock.

20 n patients with various causes of refractory cardiogenic shock.

21 be preferred over dopamine in patients with cardiogenic shock.

22 in the first 24 hours after the diagnosis of cardiogenic shock.

23 ous coronary intervention cardiac arrest and cardiogenic shock.

24 of pulmonary edema, myocardial ischemia, or cardiogenic shock.

25 owing admission to the ICU) of patients with cardiogenic shock.

26 d during the index admission from persistent cardiogenic shock.

27 ation myocardial infarction, with or without cardiogenic shock.

28 xygenation for cardiac arrest and refractory cardiogenic shock.

29 rdial infarction (50%) was the main cause of cardiogenic shock.

30 (VA-ECLS) is widely used to treat refractory cardiogenic shock.

31 ular ejection fraction, pulmonary edema, and cardiogenic shock.

32 sed for treatment of low cardiac output with cardiogenic shock.

33 cardial infarction, multivessel disease, and cardiogenic shock.

34 myocardial infarction (STEMI) complicated by cardiogenic shock.

35 nfarction (AMI) and is often associated with cardiogenic shock.

36 culatory support in patients with refractory cardiogenic shock.

37 alance (18.9%-35.3%), pneumonia (4.4%-6.3%), cardiogenic shock (0.5%-1.5%), and acute respiratory fai

38 Among 45977 patients with AMI and cardiogenic shock (11298 in New York), 21 974 (47.8%) un

39 , death presented with a higher incidence of cardiogenic shock (15 of 47 [32%] vs. 2 of 34 [6%]; p <

40 female (93% vs. 27%), and had more frequent cardiogenic shock (19% vs. 9%); all p <= 0.03.

41 ty (5.7% CsA vs. 3.2% controls, p = 0.17) or cardiogenic shock (2.4% CsA vs. 1.5% controls, p = 0.33)

42 septic shock (30%), hemorrhagic shock (15%), cardiogenic shock (20%), or no circulatory shock (35%).

43 ly with dehydration (45.4%), sepsis (41.1%), cardiogenic shock (20.9%), and diabetic ketoacidosis (16

44 Maternal complications included cardiogenic shock (24%), mechanical support (28%), urgen

45 myocardial infarction (63.2% vs. 29.6%) and cardiogenic shock (29.0% vs. 2.2%); however, among in-ho

46 dobutamine or epinephrine in the presence of cardiogenic shock (2D) and atropine in the presence of s

47 ilure (7%), sepsis or septic shock (5%), and cardiogenic shock (5%).

48 more frequently presented with heart failure/cardiogenic shock (50% versus 7%; P<0.01), requiring int

49 segment-elevation myocardial infarction with cardiogenic shock (8.4% versus 4.3%).

50 y on the severe end of the KD spectrum, with cardiogenic shock a common presentation together with ot

51 had more major or life-threatening bleeding, cardiogenic shock, acute kidney injury (stage II or III)

52 t myocarditis with biventricular failure and cardiogenic shock, acutely manifested with hypotension a

53 Cardiogenic shock after acute myocardial infarction is a

54 t-ventricular assist device in patients with cardiogenic shock after acute myocardial infarction.

55 iac power index at 24 hours in patients with cardiogenic shock after acute myocardial infarction.

56 outcome by mild therapeutic hypothermia for cardiogenic shock after acute myocardial infarction.

57 Acute cardiogenic shock after myocardial infarction is associa

58 Two patients died of cardiogenic shock after the dissection.

59 ion for refractory ventricular arrhythmia in cardiogenic shock allowed successful weaning from mechan

60 pressure and cardiac output in patients with cardiogenic shock although potentially at the expense of

61 the outcomes of acute myocardial infarction-cardiogenic shock (AMI-CS) in young adults.

62 n acute myocardial infarction complicated by cardiogenic shock (AMI-CS), despite limited evidence for

63 s in the care of acute myocardial infarction-cardiogenic shock (AMI-CS).

64 e myocardial infarction (AMI) complicated by cardiogenic shock (AMICS).

65 a significant increase in the use of PCI for cardiogenic shock and a concomitant decrease in in-hospi

66 auses of death within the first 30 days were cardiogenic shock and anoxic brain injury after cardiac

67 0.5% and 0.3% AMI admissions complicated by cardiogenic shock and cardiac arrest, respectively.

68 herapeutic option for patients with advanced cardiogenic shock and cardiac arrest.

69 ained acute brain injury as a consequence of cardiogenic shock and cardiac arrest.

70 microcirculation in patients with refractory cardiogenic shock and compared the evolutions of those p

71 All 21 consecutive patients with cardiogenic shock and concomitant refractory ventricular

72 entricular tachycardia (VT) in patients with cardiogenic shock and concomitant VT refractory to antia

73 The first two treated patients developed cardiogenic shock and died within a few days of T-cell i

74 ality compared with those who presented with cardiogenic shock and later developed ventricular arrhyt

75 membrane oxygenation in patients with severe cardiogenic shock and little/no residual left ventricula

76 me (SIRS) frequently occurs in patients with cardiogenic shock and may aggravate shock severity and o

77 atients with acute coronary syndrome-related cardiogenic shock and may help therapeutic decision maki

78 emale, and had more comorbidities, including cardiogenic shock and multivessel disease.

79 n (AF) influences prognosis in patients with cardiogenic shock and multivessel disease.

80 zards models to test the association between cardiogenic shock and outcomes, adjusting for patient an

81 sought to evaluate the associations between cardiogenic shock and post-discharge mortality and all-c

82 porary stabilization of otherwise refractory cardiogenic shock and serve as a bridge-to-decision ther

83 e oxygenation (88%) (nine cardiac arrest; 13 cardiogenic shock) and three had venovenous extracorpore

84 lcohol use, STEMI acuity (cardiac arrest and cardiogenic shock), and hospital characteristics.

85 rial extracorporeal membrane oxygenation for cardiogenic shock, and 3) extracorporeal cardiopulmonary

86 Nearly 4% were in cardiogenic shock, and 5.2% were on mechanical ventilati

87 coronary intervention, those presenting with cardiogenic shock, and acute decompensated heart failure

88 es, higher peak troponin levels, in-hospital cardiogenic shock, and cardiology follow-up within 2 wee

89 with cardiogenic shock, the hemodynamics of cardiogenic shock, and hemodynamic effects of percutaneo

90 h in-hospital post-procedural heart failure, cardiogenic shock, and mortality.

91 ST-segment-elevation myocardial infarction, cardiogenic shock, and multivessel disease, and were ass

92 ST-segment elevation myocardial infarction, cardiogenic shock, and out-of-hospital cardiac arrest we

93 s all-cause death, congestive heart failure, cardiogenic shock, and recurrent myocardial infarction w

94 nd point of death, congestive heart failure, cardiogenic shock, and reinfarction (adjusted odds ratio

95 mellitus, renal dysfunction, cardiac arrest, cardiogenic shock, and ST-segment elevation myocardial i

96 events (MACE) were defined as a composite of cardiogenic shock, arrest, complete heart block, and car

97 t in patients with refractory postcardiotomy cardiogenic shock assisted with venoarterial extracorpor

98 was significantly higher among patients with cardiogenic shock at 60 days (9.6% vs. 5.5%) and 1 year

99 point of death, congestive heart failure, or cardiogenic shock at 90 days (adjusted HR, 2.4; 95% CI,

100 patients who underwent PCI in the setting of cardiogenic shock at one of 1429 National Cardiovascular

101 iods between 2001 and 2011, who did not have cardiogenic shock at the time of hospital presentation.

102 of death, malignant ventricular arrhythmia, cardiogenic shock, atrioventricular block, and reinfarct

103 Two patients died secondary to cardiogenic shock before imaging studies.

104 ving extracorporeal membrane oxygenation for cardiogenic shock, but the shape of this relationship is

105 atient features, treatments, and outcomes of cardiogenic shock by MI classification: ST-segment-eleva

106 Cardiogenic shock can occur due to acute ischaemic or no

107 Consecutive patients with refractory cardiogenic shock (cardiac arrest excluded) who required

108 Hypoxic piglets had cardiogenic shock (cardiac output 58% +/- 1% of baseline

109 In addition to known predictors of delay (cardiogenic shock, cardiac arrest, and prolonged door-in

110 e previously shown that neonates in profound cardiogenic shock caused by a severe Ebstein anomaly can

111 Patients with cardiogenic shock caused by acute coronary syndrome (n=1

112 Mortality in cardiogenic shock complicating acute coronary syndrome i

113 Conclusions In cardiogenic shock complicating acute myocardial infarcti

114 the prognostic impact of AF in patients with cardiogenic shock complicating acute myocardial infarcti

115 Patients with cardiogenic shock complicating acute myocardial infarcti

116 nderwent coronary artery bypass grafting for cardiogenic shock complicating acute myocardial infarcti

117 ta on acute noncardiac multiorgan failure in cardiogenic shock complicating acute myocardial infarcti

118 ild therapeutic hypothermia in patients with cardiogenic shock complicating acute myocardial infarcti

119 for acute decompensated heart failure (i.e., cardiogenic shock complicating chronic cardiomyopathy) h

120 mized studies suggests that in patients with cardiogenic shock complicating ST-segment-elevation myoc

121 nts with multivessel disease presenting with cardiogenic shock complicating ST-segment-elevation myoc

122 use of underlying disease, the management of cardiogenic shock consists of vasopressors and inotropes

123 Women are more likely to suffer and die from cardiogenic shock (CS) as the most severe complication o

124 A new 5-stage cardiogenic shock (CS) classification scheme was recentl

125 Risk stratifying patients with cardiogenic shock (CS) is a major unmet need.

126 Cardiogenic shock (CS) is a multifactorial, hemodynamica

127 -term trends of the incidence and outcome of cardiogenic shock (CS) patients are scarce.

128 Mortality in cardiogenic shock (CS) remains high.

129 e myocardial infarction (AMI) complicated by cardiogenic shock (CS) remains high.

130 33% had acute myocardial infarction-related cardiogenic shock (CS), 31% had CS not related to acute

131 Shock type was varied, with 66% assessed as cardiogenic shock (CS), 7% as distributive, 3% as hypovo

132 transforming the management and outcomes of cardiogenic shock (CS).

133 progress has been made in the management of cardiogenic shock (CS).

134 or myocardial infarction (MI) complicated by cardiogenic shock (CS).

135 d multivariable adjusted odds of dying after cardiogenic shock declined during the most recent study

136 y, the use of IABP in the setting of PCI for cardiogenic shock decreased over time without a concurre

137 was observed for the subset of patients with cardiogenic shock, decreasing from 51.6% to 43.1% (p for

138 it Lesion Only PCI Versus Multivessel PCI in Cardiogenic Shock) demonstrated superior outcome for cul

139 intractable refractory arrhythmic storm and cardiogenic shock despite optimal medical therapy were i

140 se-fatality rates for patients who developed cardiogenic shock during hospitalization for an acute my

141 Among 112,668 AMI survivors, 5% had cardiogenic shock during hospitalization.

142 On average, 3.7% of these patients developed cardiogenic shock during their acute hospitalization wit

143 In advanced cardiogenic shock, early mechanical circulatory support

144 ts who have acute myocardial infarction with cardiogenic shock, early revascularization of the culpri

145 licly reported outcomes), 2006-2007 (time 2: cardiogenic shock excluded on a trial basis), and 2008 a

146 ial basis), and 2008 and thereafter (time 3: cardiogenic shock excluded permanently) in New York and

147 The severity of cardiogenic shock following asystolic cardiac arrest is

148 Cardiogenic shock following cardiopulmonary resuscitatio

149 e been fundamental to resuscitation of acute cardiogenic shock for decades.

150 tients undergoing PCI for AMI complicated by cardiogenic shock from 2015 to 2017, use of an intravasc

151 atients (63.6+/-12.2 years; 81.7% male) with cardiogenic shock from acute myocardial infarction recei

152 In patients with acute cardiogenic shock from acute myocardial infarction, Impe

153 The exclusion of patients with ongoing cardiogenic shock from New York PCI public reports in 20

154 ents with anoxic brain injury and refractory cardiogenic shock from public reporting has made them mo

155 creased substantially after the exclusion of cardiogenic shock from public reporting in New York, the

156 001 for time 3 vs 1]) after the exclusion of cardiogenic shock from public reporting in New York.

157 2006, New York began excluding patients with cardiogenic shock from the publicly reported percutaneou

158 urvival rates with the myocardial infarction/cardiogenic shock group used as the reference.

159 The natural history of cardiogenic shock has improved significantly with the ut

160 tion therapy, the prognosis of patients with cardiogenic shock has remained poor.

161 ents with sepsis-induced cardiomyopathy with cardiogenic shock have a high mortality.

162 Hospital survivors of AMI who had cardiogenic shock have a higher risk of death and/or hos

163 (AMI) complicated by acute heart failure or cardiogenic shock have high mortality with conventional

164 However, the majority of patients with cardiogenic shock have multivessel disease, and whether

165 Cardiogenic shock, heart failure signs/symptoms, and non

166 art Association class IV (HR=4.42; P=0.002), cardiogenic shock (HR=3.75; P=0.003), creatinine (HR=1.0

167 g IABP-SHOCK II (Intraaortic Balloon Pump in Cardiogenic Shock II) trial inclusion and exclusion crit

168 y syndrome in 62%, heart failure in 46%, and cardiogenic shock in 11%.

169 ft ventricular ejection fraction in 27+/-9%; cardiogenic shock in 23%, and electrical storm in 62% of

170 n was present in 64% (n = 46) and postarrest cardiogenic shock in 36% (n = 26) of the patients at ven

171 ces (CF-VADs) in the treatment of refractory cardiogenic shock in Interagency Registry for Mechanical

172 ts with myocardial infarction complicated by cardiogenic shock in New York and Michigan, 905 (42.6%)

173 The diagnosis of STEMI and cardiogenic shock in older patients decreased significan

174 ncidence and hospital case-fatality rates of cardiogenic shock in patients hospitalized with acute my

175 refractory arrhythmic storm responsible for cardiogenic shock in patients resistant to antiarrhythmi

176 Cardiogenic shock in patients with STEMI was associated

177 rdiac output in critically ill patients with cardiogenic shock in the intensive care.

178 Heart failure and cardiogenic shock, in severe cases, are syndromes charac

179 3 calendar year periods: 2002-2005 (time 1: cardiogenic shock included in publicly reported outcomes

180 The current pharmacological treatment for cardiogenic shock includes inotropes, vasopressors and d

181 ulatory support devices for the treatment of cardiogenic shock, including current evidence, contraind

182 membrane oxygenation in adult patients with cardiogenic shock, including epidemiology of cardiogenic

183 Cardiogenic shock, increasing pulmonary/systemic flow ra

184 cardiogenic shock, including epidemiology of cardiogenic shock, indications, contraindications, and t

185 bypass graft surgery, myocardial infarction/cardiogenic shock, injury, and infection/septic shock.

186 portunity to rapidly stabilize patients with cardiogenic shock involving the RV.

187 Cardiogenic shock is a deadly complication of an acute m

188 Cardiogenic shock is a high-acuity, potentially complex,

189 Cardiogenic shock is a highly morbid condition in which

190 h acute myocardial infarction complicated by cardiogenic shock is associated with a high in-hospital

191 Cardiogenic shock is associated with high mortality in p

192 e myocardial infarction (AMI) complicated by cardiogenic shock is associated with substantial morbidi

193 h acute myocardial infarction complicated by cardiogenic shock is highly complex, and outcomes may de

194 zation of PCI in older adults with STEMI and cardiogenic shock is increasing and paralleled by a subs

195 membrane oxygenation to support patients in cardiogenic shock is limited to isolated case reports an

196 d reperfusion in patients with STEMI without cardiogenic shock is safe and feasible.

197 tem blocker therapy in patients with ongoing cardiogenic shock is unknown.

198 atric intensive care units in 14 centers for cardiogenic shock, left ventricular dysfunction, and sev

199 ng abdominal CT in patients with unexplained cardiogenic shock may allow an earlier diagnosis.

200 Cardiogenic shock may compromise patient autonomy, or th

201 tion between hemodynamic variables and early cardiogenic shock mortality in critically ill patients.

202 nfection/septic shock, myocardial infarction/cardiogenic shock (n=1705), and coronary artery bypass g

203 Cardiogenic shock occurred in 12.2% of patients with STE

204 Postcardiotomy cardiogenic shock occurs in 2-6% of patients undergoing

205 rongest predictors of in-hospital death were cardiogenic shock (odds ratio, 6.01; 95% confidence inte

206 he rivaroxaban group; this patient died from cardiogenic shock on day 50 after a type A aortic dissec

207 Patients who had ventricular arrhythmia and cardiogenic shock on presentation had a trend toward low

208 ve, 0.77 at 12 hr up to 0.93 at 5-10 d after cardiogenic shock onset).

209 gastrointestinal bleeding or to present with cardiogenic shock or after cardiac arrest.

210 Patients with cardiogenic shock or cardiac arrest on presentation were

211 ve heart failure (OR, 1.7; 95% CI, 1.3-2.2), cardiogenic shock (OR, 5.4; 95% CI, 2.7-10.9), and fluid

212 56 to 0.71) or concomitant cardiac arrest or cardiogenic shock (OR: 0.58, 95% CI: 0.47 to 0.70).

213 rt failure (OR: 1.33; 95% CI: 1.17 to 1.52), cardiogenic shock (OR: 1.26; 95% CI: 1.08 to 1.48), and

214 ith a preimplantation profile of 1 (critical cardiogenic shock) or 2 (progressive decline) were asses

215 hemodynamic decompensation with hypotension, cardiogenic shock, or cardiac arrest.

216 cardiovascular death, myocardial infarction, cardiogenic shock, or heart failure) and secondary outco

217 cardiovascular death, myocardial infarction, cardiogenic shock, or heart failure.

218 85 years of age admitted for heart failure, cardiogenic shock, or LVAD implantation from 2012 to 201

219 onship between hemodynamic variables and the cardiogenic shock outcome in critically ill patients.

220 nintended consequence of public reporting of cardiogenic shock outcomes in New York.

221 ne in the death, but not incidence, rates of cardiogenic shock over time.

222 -segment-elevation myocardial infarction and cardiogenic shock (P<0.001).

223 dritic cell death compared to normal sera or cardiogenic shock (p<0.005).

224 ogically-based approach to management of the cardiogenic shock patient on extracorporeal membrane oxy

225 oreal membrane oxygenation management in the cardiogenic shock patient.

226 ew is to discuss four sub-classifications of cardiogenic shock patients (acute myocardial infarction,

227 stics, the risk of death remained higher for cardiogenic shock patients in the first 60 days after di

228 ion (ECMO) has allowed approximately half of cardiogenic shock patients to receive an implantable lef

229 did not affect microcirculation variables in cardiogenic shock patients with little/no residual left

230 rporeal membrane oxygenation to treat severe cardiogenic shock patients, microcirculation data in thi

231 endently associated with 28-day mortality in cardiogenic shock patients.

232 it Lesion Only PCI versus Multivessel PCI in Cardiogenic Shock), patients were grouped according to t

233 it Lesion Only PCI Versus Multivessel PCI in Cardiogenic Shock), patients with CS complicating acute

234 EDLINE search was conducted with MeSH terms: cardiogenic shock, percutaneous mechanical circulatory s

235 terms: extracorporeal membrane oxygenation, cardiogenic shock, percutaneous mechanical circulatory s

236 indications for ECMO include cardiac arrest, cardiogenic shock, post-cardiotomy shock, refractory ven

237 tive COVID-19 with nonanterior STEMI without cardiogenic shock, PPCI offered a 0.4% absolute mortalit

238 For patients with presumptive COVID-19 with cardiogenic shock, PPCI offered substantial mortality be

239 tation after cardiac arrest, presentation in cardiogenic shock, presentation in heart failure, presen

240 e in patients with myocardial infarction and cardiogenic shock prior to cardiogenic shock resolution.

241 culatory support in patients with refractory cardiogenic shock providing a bridge to long-term mechan

242 of patients undergoing PCI in the setting of cardiogenic shock received an IABP and 6.7% received O-M

243 enation (VA-ECMO) support for sepsis-induced cardiogenic shock refractory to conventional treatments.

244 tments are insufficient for the treatment of cardiogenic shock refractory to inotropic support, there

245 Mortality for refractory cardiogenic shock remains high.

246 he mortality rate associated with refractory cardiogenic shock remains markedly elevated, with INTERM

247 Today, cardiogenic shock remains the leading cause of death amo

248 Mortality from cardiogenic shock remains unacceptably high despite earl

249 ort, the independent predictors of MACE were cardiogenic shock, renal disease, history of peripheral

250 riority "status" tiers from 3 to 6 and added cardiogenic shock requirements for some heart transplant

251 Severe cases can present as vasodilatory or cardiogenic shock requiring fluid resuscitation, inotrop

252 everely impaired in patients with refractory cardiogenic shock requiring venoarterial extracorporeal

253 refractory arrhythmic storm responsible for cardiogenic shock resistant to antiarrhythmic drugs.

254 otensin-aldosterone system blockers prior to cardiogenic shock resolution (27.3% vs 16.9%; adjusted h

255 al infarction and cardiogenic shock prior to cardiogenic shock resolution.

256 the use of temporary circulatory support for cardiogenic shock, reviews the evidence informing indica

257 gy, pathophysiology, causes, and outcomes of cardiogenic shock; reviews contemporary best medical, su

258 Multiple organ failure and early cardiogenic shock seem to markedly impact the prognosis,

259 Inhibition of inflammation during cardiogenic shock seems to be a potential therapeutic ta

260 g VAD is feasible in a variety of refractory cardiogenic shock settings.

261 SAVR was associated with higher risk of cardiogenic shock, severe bleeding, and acute kidney inj

262 se in acute myocardial infarction (AMI) with cardiogenic shock, ST elevation acute coronary syndromes

263 This scientific statement on cardiogenic shock summarizes the epidemiology, pathophys

264 s with acute myocardial infarction (AMI) and cardiogenic shock survive hospitalization; little is kno

265 provider infection risk based on presence of cardiogenic shock, suspected coronary territory, and pre

266 luding all-cause death, cardiac arrest, AMI, cardiogenic shock, sustained ventricular arrhythmia, and

267 main or left anterior descending culprit and cardiogenic shock than STEMI-ATH.

268 disease and acute myocardial infarction with cardiogenic shock, the 30-day risk of a composite of dea

269 hey group using ECMO for therapy of advanced cardiogenic shock, the application of ECMO is described.

270 e the contemporary outcomes of patients with cardiogenic shock, the hemodynamics of cardiogenic shock

271 tients undergoing PCI for AMI complicated by cardiogenic shock, the mean (SD) age was 65.0 (12.6) yea

272 mong patients with myocardial infarction and cardiogenic shock, the risk of death or renal-replacemen

273 el disease, acute myocardial infarction, and cardiogenic shock to one of two initial revascularizatio

274 tion fraction, acute to chronic disease, and cardiogenic shock to preserved perfusion states.

275 left ventricular unloading in patients with cardiogenic shock treated with VA-ECMO and call for furt

276 Patients with severe sepsis-induced cardiogenic shock treated with VA-ECMO had a large and s

277 left ventricular unloading in patients with cardiogenic shock treated with VA-ECMO was associated wi

278 Data from 686 consecutive patients with cardiogenic shock treated with VA-ECMO with or without l

279 ciated with lower mortality in patients with cardiogenic shock treated with VA-ECMO, despite higher c

280 h decreased mortality in adult patients with cardiogenic shock treated with VA-ECMO.

281 e IABP-SHOCK II (Intraaortic Balloon Pump in Cardiogenic Shock) trial.

282 rt study of patients with AMI complicated by cardiogenic shock undergoing PCI between October 1, 2015

283 Patients (n=40) with cardiogenic shock undergoing primary percutaneous corona

284 cute myocardial infarction, unstable angina, cardiogenic shock, ventricular arrhythmia, atrioventricu

285 mation often leading to death resulting from cardiogenic shock, ventricular arrhythmias, or multiorga

286 onia (n=1 in the dulaglutide 0.75 mg group); cardiogenic shock; ventricular fibrillation; and an unkn

287 ase-fatality rate for patients who developed cardiogenic shock was 41.4%.

288 The cause of refractory cardiogenic shock was failure of medical management in 7

289 Until recently, there were few options if cardiogenic shock was refractory to vasopressors or intr

290 ansplantation, INTERMACS profile 1 (critical cardiogenic shock) was present in 207 patients, INTERMAC

291 with septic shock and not patients with pure cardiogenic shock were characterized by a rapid and prof

292 Patients in cardiogenic shock were excluded.

293 segment-elevation myocardial infarction, and cardiogenic shock were included.

294 complicating physiology (eg, hypovolemia or cardiogenic shock), while invasive hemodynamic monitorin

295 s used to assemble a cohort of patients with cardiogenic shock with similar baseline characteristics

296 After excluding patients with cardiogenic shock, with previous bypass surgery, or who

297 tio, 1.22; 95% CI, 1.03-1.46; p = 0.025) and cardiogenic shock within 48 hours post-ICU admission (od

298 Thirty-five patients (38%) developed cardiogenic shock within the first 48 hours after ICU ad

299 ving extracorporeal membrane oxygenation for cardiogenic shock without evidence of a threshold effect

300 e [<75 years vs >/=75 years] and presence of cardiogenic shock [yes vs no]) to heparin (70 U/kg) or b